{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T10:01:51Z","timestamp":1789639311951,"version":"4.0.0"},"reference-count":65,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T00:00:00Z","timestamp":1784592000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T00:00:00Z","timestamp":1784592000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Acta Pharmacol Sin"],"published-print":{"date-parts":[[2026,10]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Synthetic cannabinoid receptor agonists (SCRAs) are a large group of structurally diverse designer drugs (analogues of controlled substances) associated with intense and sometimes fatal intoxication. Cardiac symptoms, including tachycardia and arrhythmia, are common consequences of SCRA consumption. However, little is known about the mechanisms through which SCRAs may perturb cardiac rhythm. Here, we used electrophysiological techniques to screen 36 SCRAs on two ion channels responsible for cardiomyocyte repolarization, hERG (also called K\n                    <jats:sub>V<\/jats:sub>\n                    11.1) and K\n                    <jats:sub>V<\/jats:sub>\n                    7.1\/KCNE1. We report that the majority of tested SCRAs inhibited hERG, primarily by reducing channel conductance, and some also inhibited K\n                    <jats:sub>V<\/jats:sub>\n                    7.1\/KCNE1. In silico data suggest that SCRAs may use both a known drug binding site in the central cavity of the hERG channel, shared by established hERG blockers like astemizole, and a recently identified side pocket site. Experimental and in silico data suggest SCRA structural features associated with prominent inhibitory effects on hERG, with chemical moieties allowing bond formation and\/or the ability to fit into binding sites being important. Structure-activity relationships (SAR) for SCRA effects on hERG, K\n                    <jats:sub>V<\/jats:sub>\n                    7.1\/KCNE1 and the cannabinoid receptor 1 (CB\n                    <jats:sub>1<\/jats:sub>\n                    ) varied, demonstrating the need to assess SCRA effects on multiple potential targets. In conclusion, we found SCRAs to be inhibitors of cardiac voltage-gated potassium channels important for cardiomyocyte repolarization, highlighting the importance of more extensive investigation of SCRAs on cardiac function.\n                  <\/jats:p>","DOI":"10.1038\/s41401-026-01876-9","type":"journal-article","created":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T02:20:03Z","timestamp":1784600403000},"page":"2940-2954","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Synthetic cannabinoid receptor agonists inhibit the cardiac voltage-gated potassium channel hERG"],"prefix":"10.1038","volume":"47","author":[{"given":"Nina E.","family":"Ottosson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Damon J. A.","family":"Frampton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tanadet","family":"Pipatpolkai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caitlyn","family":"Norman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Urban","family":"Karlsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amaia","family":"Jauregi-Miguel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maryke","family":"Venter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akshay","family":"Sridhar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H. Peter","family":"Larsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henrik","family":"Gr\u00e9en","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara I.","family":"Liin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,21]]},"reference":[{"key":"1876_CR1","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1007\/164_2018_143","volume":"252","author":"SD Banister","year":"2018","unstructured":"Banister SD, Connor M. The chemistry and pharmacology of synthetic cannabinoid receptor agonists as new psychoactive substances: origins. Handb Exp Pharmacol. 2018;252:165\u201390.","journal-title":"Handb Exp Pharmacol"},{"key":"1876_CR2","unstructured":"European Union Drugs A. European Drug Report 2025: trends and developments. Luxembourg, 2025."},{"key":"1876_CR3","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.brainresbull.2016.04.013","volume":"126","author":"G Loeffler","year":"2016","unstructured":"Loeffler G, Delaney E, Hann M. International trends in spice use: prevalence, motivation for use, relationship to other substances, and perception of use and safety for synthetic cannabinoids. Brain Res Bull. 2016;126:8\u201328.","journal-title":"Brain Res Bull"},{"key":"1876_CR4","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1002\/dta.3002","volume":"13","author":"C Norman","year":"2021","unstructured":"Norman C, Halter S, Haschimi B, Acreman D, Smith J, Krotulski AJ, et al. A transnational perspective on the evolution of the synthetic cannabinoid receptor agonists market: comparing prison and general populations. Drug Test Anal. 2021;13:841\u201352.","journal-title":"Drug Test Anal"},{"key":"1876_CR5","doi-asserted-by":"publisher","first-page":"2322","DOI":"10.1007\/s11469-022-00988-7","volume":"22","author":"T Coombs","year":"2024","unstructured":"Coombs T, Ginige T, Van Calster P, Abdelkader A, Corazza O, Assi S. New psychoactive substances in the homeless population: a cross-sectional study in the United Kingdom. Int J Ment Health Addict. 2024;22:2322\u201337.","journal-title":"Int J Ment Health Addict"},{"key":"1876_CR6","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1111\/ajad.13482","volume":"33","author":"J Stogner","year":"2024","unstructured":"Stogner J, Santangelo O, Baldwin JM. Brief report: Synthetic cannabinoid use among military personnel. Am J Addict. 2024;33:96\u20139.","journal-title":"Am J Addict"},{"key":"1876_CR7","doi-asserted-by":"crossref","unstructured":"Grace S, Lloyd C, Perry A. The spice trail: Transitions in synthetic cannabis receptor agonists (SCRAs) use in English prisons and on release. Drug Educ Prev Policy. 2019;27:271\u201381.","DOI":"10.1080\/09687637.2019.1684878"},{"key":"1876_CR8","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1007\/s13181-024-01013-0","volume":"20","author":"A Gould","year":"2024","unstructured":"Gould A, Dargan PI, Wood DM. An internet snapshot survey assessing the sale of synthetic cannabinoid receptor agonists for use with electronic vaping devices. J Med Toxicol. 2024;20:271\u20137.","journal-title":"J Med Toxicol"},{"key":"1876_CR9","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugpo.2021.103493","volume":"100","author":"PE Oomen","year":"2022","unstructured":"Oomen PE, Schori D, Togel-Lins K, Acreman D, Chenorhokian S, Luf A, et al. Cannabis adulterated with the synthetic cannabinoid receptor agonist MDMB-4en-PINACA and the role of European drug checking services. Int J Drug Policy. 2022;100:103493.","journal-title":"Int J Drug Policy"},{"key":"1876_CR10","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.1002\/dta.3220","volume":"14","author":"MC Monti","year":"2022","unstructured":"Monti MC, Zeugin J, Koch K, Milenkovic N, Scheurer E, Mercer-Chalmers-Bender K. Adulteration of low-delta-9-tetrahydrocannabinol products with synthetic cannabinoids: results from drug checking services. Drug Test Anal. 2022;14:1026\u201339.","journal-title":"Drug Test Anal"},{"key":"1876_CR11","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1111\/dar.13237","volume":"40","author":"L Ti","year":"2021","unstructured":"Ti L, Tobias S, Maghsoudi N, Milloy MJ, McDonald K, Shapiro A, et al. Detection of synthetic cannabinoid adulteration in the unregulated drug supply in three Canadian settings. Drug Alcohol Rev. 2021;40:580\u20135.","journal-title":"Drug Alcohol Rev"},{"key":"1876_CR12","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugpo.2021.103396","volume":"98","author":"S Darke","year":"2021","unstructured":"Darke S, Banister S, Farrell M, Duflou J, Lappin J. Synthetic cannabis: A dangerous misnomer. Int J Drug Policy. 2021;98:103396.","journal-title":"Int J Drug Policy"},{"key":"1876_CR13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3109\/15563650.2015.1110590","volume":"54","author":"RJ Tait","year":"2016","unstructured":"Tait RJ, Caldicott D, Mountain D, Hill SL, Lenton S. A systematic review of adverse events arising from the use of synthetic cannabinoids and their associated treatment. Clin Toxicol. 2016;54:1\u201313.","journal-title":"Clin Toxicol"},{"key":"1876_CR14","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1080\/15563650.2024.2346125","volume":"62","author":"ML Waters","year":"2024","unstructured":"Waters ML, Dargan PI, Yates C, Dines AM, Eyer F, Giraudon I, et al. Clinical effects of cannabis compared to synthetic cannabinoid receptor agonists (SCRAs): a retrospective cohort study of presentations with acute toxicity to European hospitals between 2013 and 2020. Clin Toxicol. 2024;62:378\u201384.","journal-title":"Clin Toxicol"},{"key":"1876_CR15","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1080\/15563650.2019.1647344","volume":"58","author":"S Darke","year":"2020","unstructured":"Darke S, Duflou J, Farrell M, Peacock A, Lappin J. Characteristics and circumstances of synthetic cannabinoid-related death. Clin Toxicol. 2020;58:368\u201374.","journal-title":"Clin Toxicol"},{"key":"1876_CR16","doi-asserted-by":"publisher","first-page":"464","DOI":"10.3389\/fpsyt.2020.00464","volume":"11","author":"A Giorgetti","year":"2020","unstructured":"Giorgetti A, Busardo FP, Tittarelli R, Auwarter V, Giorgetti R. Post-mortem toxicology: a systematic review of death cases involving synthetic cannabinoid receptor agonists. Front Psychiatry. 2020;11:464.","journal-title":"Front Psychiatry"},{"key":"1876_CR17","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1111\/jnu.12817","volume":"55","author":"A Suriaga","year":"2023","unstructured":"Suriaga A, Tappen RM, Aston ER, Chiang-Hanisko L, Newman D. Cannabinoids and synthetic cannabinoids as a cause of death: Trends and their healthcare implications. J Nurs Scholarsh. 2023;55:623\u201336.","journal-title":"J Nurs Scholarsh"},{"key":"1876_CR18","unstructured":"EMCDDA. Report on the risk assessment of methyl 2-{[1-(5-fluoropentyl)-1H-indazole-3-carbonyl]amino}-3,3-dimethylbutanoate (5F-MDMB-PINACA; 5F-ADB) in the framework of the Council Decision on New Psychoactive Substances. 2018."},{"key":"1876_CR19","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1111\/1556-4029.14098","volume":"65","author":"DM Boland","year":"2020","unstructured":"Boland DM, Reidy LJ, Seither JM, Radtke JM, Lew EO. Forty-three fatalities involving the synthetic cannabinoid, 5-fluoro-ADB: forensic pathology and toxicology implications. J Forensic Sci. 2020;65:170\u201382.","journal-title":"J Forensic Sci"},{"key":"1876_CR20","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1093\/jat\/bkz092","volume":"44","author":"JA Hvozdovich","year":"2020","unstructured":"Hvozdovich JA, Chronister CW, Logan BK, Goldberger BA. Case report: synthetic cannabinoid deaths in state of florida prisoners. J Anal Toxicol. 2020;44:298\u2013300.","journal-title":"J Anal Toxicol"},{"key":"1876_CR21","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1007\/s00414-021-02717-6","volume":"136","author":"F Gaunitz","year":"2022","unstructured":"Gaunitz F, Andresen-Streichert H. Analytical findings in a non-fatal intoxication with the synthetic cannabinoid 5F-ADB (5F-MDMB-PINACA): a case report. Int J Leg Med. 2022;136:577\u201389.","journal-title":"Int J Leg Med"},{"key":"1876_CR22","doi-asserted-by":"publisher","DOI":"10.1177\/2042098620913416","volume":"11","author":"JC Hancox","year":"2020","unstructured":"Hancox JC, Kalk NJ, Henderson G. Synthetic cannabinoids and potential cardiac arrhythmia risk: an important message for drug users. Ther Adv Drug Saf. 2020;11:2042098620913416.","journal-title":"Ther Adv Drug Saf"},{"key":"1876_CR23","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1016\/j.hrcr.2020.02.002","volume":"6","author":"T Ahmed","year":"2020","unstructured":"Ahmed T, Khan A, See VY, Robinson S. Cardiac arrest associated with synthetic cannabinoid use and acquired prolonged QTc interval: a case report and review of literature. HeartRhythm Case Rep. 2020;6:283\u20136.","journal-title":"HeartRhythm Case Rep"},{"key":"1876_CR24","volume":"2014","author":"S Ibrahim","year":"2014","unstructured":"Ibrahim S, Al-Saffar F, Wannenburg T. A unique case of cardiac arrest following K2 abuse. Case Rep Cardiol. 2014;2014:120607.","journal-title":"Case Rep Cardiol"},{"key":"1876_CR25","first-page":"384","volume":"47","author":"SS Yildiz","year":"2019","unstructured":"Yildiz SS, Sutasir MN, Sigirci S, Topcu H, Gurdal A, Keskin K, et al. Acute effects of synthetic cannabinoids on ventricular repolarization parameters. Turk Kardiyol Dern Ars. 2019;47:384\u201390.","journal-title":"Turk Kardiyol Dern Ars"},{"key":"1876_CR26","doi-asserted-by":"publisher","first-page":"1663","DOI":"10.1039\/C6TX00259E","volume":"5","author":"J Yun","year":"2016","unstructured":"Yun J, Yoon KS, Lee TH, Lee H, Gu SM, Song YJ, et al. Synthetic cannabinoid, JWH-030, induces QT prolongation through hERG channel inhibition. Toxicol Res. 2016;5:1663\u201371.","journal-title":"Toxicol Res"},{"key":"1876_CR27","doi-asserted-by":"crossref","unstructured":"Cheng H, Upex C, Du C, Copeland C, Henderson G, Harmer SC, et al. Noncanonical pharmacological inhibition of the hERG K+ channel by a synthetic cannabinoid. Biochem Pharmacol. 2025;242:117257.","DOI":"10.1016\/j.bcp.2025.117257"},{"key":"1876_CR28","volume":"6","author":"JC Hancox","year":"2023","unstructured":"Hancox JC, Copeland CS, Harmer SC, Henderson G. New synthetic cannabinoids and the potential for cardiac arrhythmia risk. J Mol Cell Cardiol. 2023;6:100049.","journal-title":"J Mol Cell Cardiol"},{"key":"1876_CR29","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1056\/NEJMra032426","volume":"350","author":"DM Roden","year":"2004","unstructured":"Roden DM. Drug-induced prolongation of the QT interval. N Engl J Med. 2004;350:1013\u201322.","journal-title":"N Engl J Med"},{"key":"1876_CR30","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1136\/heartjnl-2020-318259","volume":"108","author":"AAM Wilde","year":"2022","unstructured":"Wilde AAM, Amin AS, Postema PG. Diagnosis, management and therapeutic strategies for congenital long QT syndrome. Heart. 2022;108:332\u20138.","journal-title":"Heart"},{"key":"1876_CR31","doi-asserted-by":"crossref","unstructured":"Wang W, MacKinnon R. Cryo-EM structure of the open human ether-\u00e0-go-go-related K+ channel hERG. Cell. 2017;169:422\u201330.e10.","DOI":"10.1016\/j.cell.2017.03.048"},{"key":"1876_CR32","doi-asserted-by":"crossref","unstructured":"Asai T, Adachi N, Moriya T, Oki H, Maru T, Kawasaki M, et al. Cryo-EM structure of K+-bound hERG channel complexed with the blocker astemizole. Structure. 2021;29:203\u201312.e4.","DOI":"10.1016\/j.str.2020.12.007"},{"key":"1876_CR33","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/0014-5793(96)00355-9","volume":"385","author":"H Suessbrich","year":"1996","unstructured":"Suessbrich H, Waldegger S, Lang F, Busch AE. Blockade of HERG channels expressed in Xenopus oocytes by the histamine receptor antagonists terfenadine and astemizole. FEBS Lett. 1996;385:77\u201380.","journal-title":"FEBS Lett"},{"key":"1876_CR34","doi-asserted-by":"publisher","first-page":"1556","DOI":"10.1016\/S0735-1097(96)00352-X","volume":"28","author":"VR Vorperian","year":"1996","unstructured":"Vorperian VR, Zhou Z, Mohammad S, Hoon TJ, Studenik C, January CT. Torsade de pointes with an antihistamine metabolite: potassium channel blockade with desmethylastemizole. J Am Coll Cardiol. 1996;28:1556\u201361.","journal-title":"J Am Coll Cardiol"},{"key":"1876_CR35","doi-asserted-by":"publisher","first-page":"1926","DOI":"10.1016\/j.str.2024.08.021","volume":"32","author":"Y Miyashita","year":"2024","unstructured":"Miyashita Y, Moriya T, Kato T, Kawasaki M, Yasuda S, Adachi N, et al. Improved higher resolution cryo-EM structures reveal the binding modes of hERG channel inhibitors. Structure. 2024;32:1926\u201335 e3.","journal-title":"Structure"},{"key":"1876_CR36","doi-asserted-by":"publisher","first-page":"5557","DOI":"10.1021\/jp0708953","volume":"111","author":"N Otero","year":"2007","unstructured":"Otero N, Mandado M, Mosquera RA. Nucleophilicity of indole derivatives: activating and deactivating effects based on proton affinities and electron density properties. J Phys Chem A. 2007;111:5557\u201362.","journal-title":"J Phys Chem A"},{"key":"1876_CR37","doi-asserted-by":"crossref","unstructured":"Towart R, Linders JT, Hermans AN, Rohrbacher J, van der Linde HJ, Ercken M, et al. Blockade of the IKs potassium channel: an overlooked cardiovascular liability in drug safety screening? J Pharm Toxicol Methods. 2009;60:1\u201310.","DOI":"10.1016\/j.vascn.2009.04.197"},{"key":"1876_CR38","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2305295120","volume":"120","author":"MB Jameson","year":"2023","unstructured":"Jameson MB, R\u00edos-P\u00e9rez EB, Liu F, Eichel CA, Robertson GA. Pairwise biosynthesis of ion channels stabilizes excitability and mitigates arrhythmias. Proc Natl Acad Sci USA. 2023;120:e2305295120.","journal-title":"Proc Natl Acad Sci USA"},{"key":"1876_CR39","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1093\/cvr\/cvae042","volume":"120","author":"Y Wada","year":"2024","unstructured":"Wada Y, Wang L, Hall LD, Yang T, Short LL, Solus JF, et al. The electrophysiologic effects of KCNQ1 extend beyond expression of IKs: evidence from genetic and pharmacologic block. Cardiovasc Res. 2024;120:735\u201344.","journal-title":"Cardiovasc Res"},{"key":"1876_CR40","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1177\/10915818241237988","volume":"43","author":"E Boulay","year":"2024","unstructured":"Boulay E, Troncy E, Jacquemet V, Huang H, Pugsley MK, Downey AM, et al. In silico human cardiomyocyte action potential modeling: exploring ion channel input combinations. Int J Toxicol. 2024;43:357\u201367.","journal-title":"Int J Toxicol"},{"key":"1876_CR41","doi-asserted-by":"publisher","first-page":"e1002061","DOI":"10.1371\/journal.pcbi.1002061","volume":"7","author":"T O\u2019Hara","year":"2011","unstructured":"O\u2019Hara T, Virag L, Varro A, Rudy Y. Simulation of the undiseased human cardiac ventricular action potential: model formulation and experimental validation. PLoS Comput Biol. 2011;7:e1002061.","journal-title":"PLoS Comput Biol"},{"key":"1876_CR42","doi-asserted-by":"crossref","unstructured":"Bohannon BM, de la Cruz A, Wu X, Jowais JJ, Perez ME, Dykxhoorn DM, et al. Polyunsaturated fatty acid analogues differentially affect cardiac NaV, CaV, and KV channels through unique mechanisms. Elife. 2020;9:e51453.","DOI":"10.7554\/eLife.60141"},{"key":"1876_CR43","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1002\/dta.3422","volume":"15","author":"R Andrews","year":"2023","unstructured":"Andrews R, Jorge R, Christie R, Gallegos A. From JWH-018 to OXIZIDS: structural evolution of synthetic cannabinoids in the European Union from 2008 to the present day. Drug Test Anal. 2023;15:378\u201387.","journal-title":"Drug Test Anal"},{"key":"1876_CR44","doi-asserted-by":"crossref","unstructured":"Ong ST, Nam YW, Nasburg JA, Ramanishka A, Ng XR, Zhuang Z, et al. Design and structural basis of selective 1,4-dihydropyridine inhibitors of the calcium-activated potassium channel KCa3.1. Proc Natl Acad Sci USA. 2025;122:e2425494122.","DOI":"10.1073\/pnas.2425494122"},{"key":"1876_CR45","doi-asserted-by":"crossref","unstructured":"Tao E, Corry B. Drugs exhibit diverse binding modes and access routes in the Nav1.5 cardiac sodium channel pore. J. Gen Physiol. 2025;157:e202413658.","DOI":"10.1085\/jgp.202413658"},{"key":"1876_CR46","first-page":"1583","volume":"4","author":"J He\u0301nin","year":"2022","unstructured":"He\u0301nin J, Lelie\u0300vre T, Shirts MR, Valsson O, Delemotte L. Enhanced sampling methods for molecular dynamics simulations [Article v1.0] living J. Comp Mol Sci. 2022;4:1583.","journal-title":"Comp Mol Sci"},{"key":"1876_CR47","doi-asserted-by":"publisher","first-page":"1012","DOI":"10.1002\/dta.3621","volume":"16","author":"AM Brandon","year":"2024","unstructured":"Brandon AM, Baginski SR, Peet C, Dugard P, Green H, Sutcliffe OB, et al. Log D(7.4) and plasma protein binding of synthetic cannabinoid receptor agonists and a comparison of experimental and predicted lipophilicity. Drug Test Anal. 2024;16:1012\u201325.","journal-title":"Drug Test Anal"},{"key":"1876_CR48","doi-asserted-by":"publisher","first-page":"e9","DOI":"10.1016\/j.forsciint.2017.10.042","volume":"281","author":"V Angerer","year":"2017","unstructured":"Angerer V, Jacobi S, Franz F, Auw\u00e4rter V, Pietsch J. Three fatalities associated with the synthetic cannabinoids 5F-ADB, 5F-PB-22, and AB-CHMINACA. Forensic Sci Int. 2017;281:e9\u2013e15.","journal-title":"Forensic Sci Int"},{"key":"1876_CR49","doi-asserted-by":"publisher","first-page":"e21","DOI":"10.1093\/jat\/bkx088","volume":"42","author":"K Usui","year":"2018","unstructured":"Usui K, Fujita Y, Kamijo Y, Kokaji T, Funayama M. Identification of 5-fluoro ADB in human whole blood in four death cases. J Anal Toxicol. 2018;42:e21\u2013e5.","journal-title":"J Anal Toxicol"},{"key":"1876_CR50","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1007\/s11419-014-0259-0","volume":"33","author":"K Hasegawa","year":"2015","unstructured":"Hasegawa K, Wurita A, Minakata K, Gonmori K, Yamagishi I, Nozawa H, et al. Identification and quantitation of 5-fluoro-ADB, one of the most dangerous synthetic cannabinoids, in the stomach contents and solid tissues of a human cadaver and in some herbal products. Forensic Toxicol. 2015;33:112\u201321.","journal-title":"Forensic Toxicol"},{"key":"1876_CR51","doi-asserted-by":"publisher","first-page":"e5","DOI":"10.1016\/j.forsciint.2016.02.024","volume":"261","author":"P Adamowicz","year":"2016","unstructured":"Adamowicz P. Fatal intoxication with synthetic cannabinoid MDMB-CHMICA. Forensic Sci Int. 2016;261:e5\u201310.","journal-title":"Forensic Sci Int"},{"key":"1876_CR52","first-page":"86","volume":"40","author":"AA Westin","year":"2016","unstructured":"Westin AA, Frost J, Brede WR, Gundersen PO, Einvik S, Aarset H, et al. Sudden cardiac death following use of the synthetic cannabinoid MDMB-CHMICA. J Anal Toxicol. 2016;40:86\u20137.","journal-title":"J Anal Toxicol"},{"key":"1876_CR53","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1007\/s13181-016-0584-2","volume":"13","author":"M B\u00e4ckberg","year":"2017","unstructured":"B\u00e4ckberg M, Tworek L, Beck O, Helander A. Analytically confirmed intoxications involving MDMB-CHMICA from the STRIDA project. J Med Toxicol. 2017;13:52\u201360.","journal-title":"J Med Toxicol"},{"key":"1876_CR54","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1080\/15563650.2017.1393082","volume":"56","author":"M Hermanns-Clausen","year":"2018","unstructured":"Hermanns-Clausen M, M\u00fcller D, Kithinji J, Angerer V, Franz F, Eyer F, et al. Acute side effects after consumption of the new synthetic cannabinoids AB-CHMINACA and MDMB-CHMICA. Clin Toxicol. 2018;56:404\u201311.","journal-title":"Clin Toxicol"},{"key":"1876_CR55","unstructured":"EMCDDA. European Drug Report 2024: Trends and developments. 2024."},{"key":"1876_CR56","doi-asserted-by":"crossref","unstructured":"Deng L, Vysotski ES, Markova SV, Liu ZJ, Lee J, Rose J, et al. All three Ca2+-binding loops of photoproteins bind calcium ions: the crystal structures of calcium-loaded apo-aequorin and apo-obelin. Protein Sci. 2005;14:663\u201375.","DOI":"10.1110\/ps.041142905"},{"key":"1876_CR57","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2019.08.025","volume":"169","author":"E Wouters","year":"2019","unstructured":"Wouters E, Walraed J, Banister SD, Stove CP. Insights into biased signaling at cannabinoid receptors: synthetic cannabinoid receptor agonists. Biochem Pharmacol. 2019;169:113623.","journal-title":"Biochem Pharmacol"},{"key":"1876_CR58","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1002\/dta.3592","volume":"16","author":"MH Deventer","year":"2024","unstructured":"Deventer MH, Persson M, Norman C, Liu H, Connolly MJ, Daeid NN, et al. In vitro cannabinoid activity profiling of generic ban-evading brominated synthetic cannabinoid receptor agonists and their analogs. Drug Test Anal. 2024;16:616\u201328.","journal-title":"Drug Test Anal"},{"key":"1876_CR59","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1002\/dta.3203","volume":"14","author":"R Kronstrand","year":"2022","unstructured":"Kronstrand R, Norman C, Vikingsson S, Biemans A, Valencia Crespo B, Edwards D, et al. The metabolism of the synthetic cannabinoids ADB-BUTINACA and ADB-4en-PINACA and their detection in forensic toxicology casework and infused papers seized in prisons. Drug Test Anal. 2022;14:634\u201352.","journal-title":"Drug Test Anal"},{"key":"1876_CR60","doi-asserted-by":"crossref","unstructured":"Truver MT, Watanabe S, Astrand A, Vikingsson S, Green H, Swortwood MJ, et al. 5F-MDMB-PICA metabolite identification and cannabinoid receptor activity. Drug Test Anal. 2020;12:127\u201335.","DOI":"10.1002\/dta.2688"},{"key":"1876_CR61","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1002\/jcc.21334","volume":"31","author":"O Trott","year":"2010","unstructured":"Trott O, Olson AJ. AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. J Comput Chem. 2010;31:455\u201361.","journal-title":"J Comput Chem"},{"key":"1876_CR62","doi-asserted-by":"publisher","first-page":"1997","DOI":"10.1002\/jcc.23702","volume":"35","author":"EL Wu","year":"2014","unstructured":"Wu EL, Cheng X, Jo S, Rui H, Song KC, D\u00e1vila-Contreras EM, et al. CHARMM-GUI membrane builder toward realistic biological membrane simulations. J Comput Chem. 2014;35:1997\u20132004.","journal-title":"J Comput Chem"},{"key":"1876_CR63","doi-asserted-by":"publisher","first-page":"3684","DOI":"10.1063\/1.448118","volume":"81","author":"HJC Berendsen","year":"1984","unstructured":"Berendsen HJC, Postma JPM, van Gunsteren WF, DiNola A, Haak JR. Molecular dynamics with coupling to an external bath. J Chem Phys. 1984;81:3684\u201390.","journal-title":"J Chem Phys"},{"key":"1876_CR64","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.softx.2015.06.001","volume":"1-2","author":"MJ Abraham","year":"2015","unstructured":"Abraham MJ, Murtola T, Schulz R, P\u00e1ll S, Smith JC, Hess B, et al. GROMACS: high-performance molecular simulations through multi-level parallelism from laptops to supercomputers. SoftwareX. 2015;1-2:19\u201325.","journal-title":"SoftwareX"},{"key":"1876_CR65","doi-asserted-by":"crossref","unstructured":"Lindahl V, Lidmar J, Hess B. Accelerated weight histogram method for exploring free energy landscapes. J Chem Phys. 2014;141:044110.","DOI":"10.1063\/1.4890371"}],"container-title":["Acta Pharmacologica Sinica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41401-026-01876-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41401-026-01876-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41401-026-01876-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T09:02:16Z","timestamp":1789635736000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41401-026-01876-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,21]]},"references-count":65,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["1876"],"URL":"https:\/\/doi.org\/10.1038\/s41401-026-01876-9","relation":{},"ISSN":["1671-4083","1745-7254"],"issn-type":[{"value":"1671-4083","type":"print"},{"value":"1745-7254","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,21]]},"assertion":[{"value":"11 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}]}}